In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
In the latest session, Biomerica Inc. (NASDAQ: BMRA) closed at $0.53 down -19.95% from its previous closing price of $0.67. In other words, the price has decreased by -$19.95 from its previous closing price. On the day, 6.97 million shares were traded. BMRA stock price reached its highest trading level at $0.7885 during the session, while it also had its lowest trading level at $0.5.
Ratios:
For a deeper understanding of Biomerica Inc.’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.37 and its Current Ratio is at 4.44. In the meantime, Its Debt-to-Equity ratio is 0.11 whereas as Long-Term Debt/Eq ratio is at 0.07.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Colliers Securities on November 10, 2020, initiated with a Buy rating and assigned the stock a target price of $13.
On January 04, 2018, B. Riley FBR Inc. started tracking the stock assigning a Buy rating and target price of $7.50.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on May 25 ’23 when Irani Zackary S. bought 200 shares for $1.55 per share. The transaction valued at 310 led to the insider holds 1,020,560 shares of the business.
Irani Zackary S. bought 500 shares of BMRA for $805 on May 24 ’23. The Chief Executive Officer now owns 1,020,360 shares after completing the transaction at $1.61 per share. On May 12 ’23, another insider, Irani Zackary S., who serves as the Chief Executive Officer of the company, bought 1,700 shares for $1.17 each. As a result, the insider paid 1,989 and bolstered with 1,019,860 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BMRA now has a Market Capitalization of 11190275 and an Enterprise Value of 4500526. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.66 while its Price-to-Book (P/B) ratio in mrq is 1.15. Its current Enterprise Value per Revenue stands at 0.832 whereas that against EBITDA is -0.713.
Stock Price History:
The Beta on a monthly basis for BMRA is -0.98, which has changed by -0.60740745 over the last 52 weeks, in comparison to a change of 0.24191546 over the same period for the S&P500. Over the past 52 weeks, BMRA has reached a high of $2.13, while it has fallen to a 52-week low of $0.66. The 50-Day Moving Average of the stock is -44.39%, while the 200-Day Moving Average is calculated to be -48.33%.
Shares Statistics:
For the past three months, BMRA has traded an average of 70.18K shares per day and 816830 over the past ten days. A total of 16.82M shares are outstanding, with a floating share count of 15.59M. Insiders hold about 7.30% of the company’s shares, while institutions hold 22.27% stake in the company. Shares short for BMRA as of 1713139200 were 65809 with a Short Ratio of 0.94, compared to 1710460800 on 76728. Therefore, it implies a Short% of Shares Outstanding of 65809 and a Short% of Float of 0.42.
Earnings Estimates
The consensus estimate for the next quarter is $0, with high estimates of $0 and low estimates of $0.
Analysts are recommending an EPS of between $0 and $0 for the fiscal current year, implying an average EPS of $0.
Revenue Estimates
A total of 1 analysts have provided revenue estimates for BMRA’s current fiscal year. The highest revenue estimate was $26.59M, while the lowest revenue estimate was $26.59M, resulting in an average revenue estimate of $26.59M. In the same quarter a year ago, actual revenue was $5.34M
